News – Page 411 – Endpoints News

Roivant's ulcerative colitis drug from Pfizer shows promising data in early readout

3 years ago

Vera Therapeutics sprints to PhIII with treatment for rare kidney disease

3 years ago

Athenex to exit drug compounding business and axe 92 employees at NY plant

3 years ago

CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds

3 years ago

Updated: Drugmakers benefit 'substantially' from secondary patents on inhalers — study

3 years ago

Amgen files brief to Supreme Court ahead of oral arguments — with industry amicus support

3 years ago

Passage of FDA Modernization Act 2.0 clears the way to reduce animal testing

3 years ago

Senate Finance Chair Wyden continues fight over low pharma tax rates, this time with BMS

3 years ago

AbbVie 'Discovery Files' docuseries details the origin stories of medicines

3 years ago

IRA's inflation-linked rebates would've saved government $3.7B from 2018 to 2020 — JAMA research

3 years ago

Cancer care branding: Will City of Hope and Cancer Treatment Centers of America brands work ‘better together’?

3 years ago

MarketingRx roundup: Pfizer rolls out Covid booster social ads with influencers; AbbVie retires Humira TV

3 years ago

Jasper Therapeutics sees a stock boost after sickle cell data release; Newron lifts the veil on data for ...

3 years ago

Fibrosis startup touts mid-stage NASH trial as it moves sole candidate forward

3 years ago

After disastrous Galapagos deal, Gilead finds new rheumatoid arthritis partner

3 years ago

Every drug approved in 2022: A year of fewer new products, but gene therapy firsts and new blockbusters

3 years ago

Scoop: Bing Yao’s ArriVent lining up $145M raise, after $150M debut in 2021

3 years ago

Congressional inquiry into 'highly atypical' FDA-Biogen ties ends with damning report, no repercussions

3 years ago

Updated: Off-the-shelf cell therapy pioneer Allogene recruits a Kite vet to run R&D

3 years ago

Forge spinoff Blacksmith Medicines merges back into company two years after launch, but details are slim

3 years ago

Scoop: J&J-backed Aro Biotherapeutics eyes nine-figure raise with first trial on horizon

3 years ago

Tiny IPO closes out Nasdaq's barren biotech year

3 years ago

Exclusive: In lieu of an IPO in rocky biotech market, Apnimed lines up $80M from existing investors for two PhIII ...

3 years ago

TG crosses the finish line in MS, turning U2 component into standalone drug for biotech's second approval

3 years ago

First page Previous page 408 409 410411412 413 414 Next page Last page